STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review

285Citations
Citations of this article
278Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Triple negative breast cancer (TNBC), which is typically lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents the most aggressive and mortal subtype of breast cancer. Currently, only a few treatment options are available for TNBC due to the absence of molecular targets, which underscores the need for developing novel therapeutic and preventive approaches for this disease. Recent evidence from clinical trials and preclinical studies has demonstrated a pivotal role of signal transducer and activator of transcription 3 (STAT3) in the initiation, progression, metastasis, and immune evasion of TNBC. STAT3 is overexpressed and constitutively activated in TNBC cells and contributes to cell survival, proliferation, cell cycle progression, anti-apoptosis, migration, invasion, angiogenesis, chemoresistance, immunosuppression, and stem cells self-renewal and differentiation by regulating the expression of its downstream target genes. STAT3 small molecule inhibitors have been developed and shown excellent anticancer activities in in vitro and in vivo models of TNBC. This review discusses the recent advances in the understanding of STAT3, with a focus on STAT3's oncogenic role in TNBC. The current targeting strategies and representative small molecule inhibitors of STAT3 are highlighted. We also propose potential strategies that can be further examined for developing more specific and effective inhibitors for TNBC prevention and therapy.

References Powered by Scopus

Breast Cancer Treatment: A Review

3107Citations
N/AReaders
Get full text

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

2083Citations
N/AReaders
Get full text

Revisiting STAT3 signalling in cancer: New and unexpected biological functions

1750Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge

566Citations
N/AReaders
Get full text

Role of STAT3 signaling pathway in breast cancer

268Citations
N/AReaders
Get full text

Long non-coding RNAs towards precision medicine in gastric cancer: Early diagnosis, treatment, and drug resistance

229Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Qin, J. J., Yan, L., Zhang, J., & Zhang, W. D. (2019, May 14). STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review. Journal of Experimental and Clinical Cancer Research. BioMed Central Ltd. https://doi.org/10.1186/s13046-019-1206-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 95

68%

Researcher 25

18%

Lecturer / Post doc 10

7%

Professor / Associate Prof. 9

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 64

50%

Medicine and Dentistry 29

23%

Pharmacology, Toxicology and Pharmaceut... 22

17%

Agricultural and Biological Sciences 12

9%

Save time finding and organizing research with Mendeley

Sign up for free